Combination of Crizotinib and Osimertinib in T790M+EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

被引：6
|
作者：
Blasi, Miriam [1 ]
Kazdal, Daniel [2 ,3 ]
Thomas, Michael [1 ,3 ]
Christopoulos, Petros [1 ,3 ]
Kriegsmann, Mark [2 ,3 ]
Brandt, Regine [2 ]
Volckmar, Anna-Lena [2 ]
Kirchner, Martina [2 ]
Heussel, Claus Peter [3 ,4 ]
Stenzinger, Albrecht [2 ,3 ]
Kuon, Jonas [1 ,3 ]
机构：
[1] Heidelberg Univ, Dept Thorac Oncol, Thoraxklin, Rontgenstr 1, DE-69126 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany
[3] German Ctr Lung Res DZL, Translat Lung Res Ctr TLRC Heidelberg, Heidelberg, Germany
[4] Heidelberg Univ, Thoraxklin, Diagnost & Intervent Radiol Nucl Med, Heidelberg, Germany
来源：
CASE REPORTS IN ONCOLOGY | 2021年 / 14卷 / 01期
关键词：
Non-small cell lung cancer; EGFR mutation; MET amplification; Targeted therapy; RESISTANCE; PATIENT; INHIBITORS; GEFITINIB; MECHANISM; AZD9291;
D O I：
10.1159/000513904
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both first- and second-generation agents such as MET oncogene amplification. This report describes the successful results obtained with the combination of the third-generation TKI osimertinib with the multitargeted TKI and MET inhibitor crizotinib in a patient with EGFR-mutant NSCLC with emerging MET amplification with a tolerable toxicity profile.
引用
收藏
页码：477 / 482
页数：6
相关论文
共 50 条
  • [41] Osimertinib in the treatment of leptomeningeal disease in T790M- negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report
    Chen, Julia
    Soudy, Hussein
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (03)
  • [42] Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
    Chiang, Chi-Lu
    Huang, Hsu-Ching
    Shen, Chia-, I
    Luo, Yung-Hung
    Chen, Yuh-Min
    Chiu, Chao-Hua
    TARGETED ONCOLOGY, 2020, 15 (04) : 503 - 512
  • [43] Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
    Eide, Inger Johanne Zwicky
    Helland, Aslaug
    Ekman, Simon
    Mellemgaard, Anders
    Hansen, Karin Holmskov
    Cicenas, Saulius
    Koivunen, Jussi
    Gronberg, Bjorn Henning
    Brustugun, Odd Terje
    LUNG CANCER, 2020, 143 : 27 - 35
  • [44] Osimertinib for EGFR T790M positive non-small cell lung cancer-making it happen, turning good idea into great results
    Jiang, Tao
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S494 - S497
  • [45] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
    Nakashima, Kazuhisa
    Kimura, Madoka
    Akamatsu, Hiroaki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Ko, Ryo
    Hisamatsu, Yasushi
    Nishino, Kazumi
    Sugimoto, Takeya
    Miyashita, Yosuke
    Takahashi, Toshiaki
    Kumagai, Toru
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675
  • [46] Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
    Tang, Yan-Jei
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    CANCERS, 2022, 14 (20)
  • [47] Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
    Shi, Jingjing
    Hao, Shaoyu
    Liu, Xiantao
    Li, Yingying
    Zheng, Xin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [48] Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M
    Zam, Nur Zam
    Iskandar, Harun
    Tabri, Nur Ahmad
    Santoso, Arif
    Lihawa, Nurjannah
    Putrawan, Harry Akza
    Sandra, Ferry
    INDONESIAN BIOMEDICAL JOURNAL, 2023, 15 (05): : 336 - 340
  • [49] Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification
    Furugaki, Koh
    Fukumura, Junko
    Iwai, Toshiki
    Yorozu, Keigo
    Kurasawa, Mitsue
    Yanagisawa, Mieko
    Moriya, Yoichiro
    Yamamoto, Kaname
    Suda, Kenichi
    Mizuuchi, Hiroshi
    Mitsudomi, Tetsuya
    Harada, Naoki
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (04) : 1024 - 1032
  • [50] Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
    Lin, Yen-Ting
    Tsai, Tzu-Hsiu
    Wu, Shang-Gin
    Liu, Yi-Nan
    Yu, Chong-Jen
    Shih, Jin-Yuan
    LUNG CANCER, 2020, 145 : 1 - 9
12345